By Laura Schanberg, MD
Over 400 CARRA members, research associates, parents, patients, Arthritis Foundation leaders, representatives from the Lupus Foundation of America, Cure JM, and NIAMS, and pharma colleagues attended the CARRA Annual Meeting in Toronto, April 14-17. It was the most well-attended CARRA meeting to date! The meeting program received highly positive evaluations from attendees. Our thanks go out to the planning committee, including Stacy Ardoin, Suzanne Li, Peter Blier, and Kelly Mieszkalski, for their hard work.
CARRA offers its members several funding opportunities that leverage the CARRA network to further research, positively impact the pediatric rheumatology scientific community, and advance the CARRA mission.
The Publication Grant funding opportunity is available to researchers to support efforts required to bring existing data from collaborative research projects to publication. Small Grants are available to support projects in development; new or early investigators are encouraged to apply and will be afforded special consideration.
The CARRA Large Grant supports the development and publication of a clinical or translational project which will immediately impact research projects within CARRA or result in a larger collaborative grant that furthers the CARRA mission.
For more information on these opportunities, please visit the Grants & Funding page.
With 1,230 subjects enrolled in the CARRA Registry at 50 sites, we are on track to enroll approximately 3300 by the end of the year. We have posted two articles with enrollment tips, https://carragroup.org/chop-tips/ and https://carragroup.org/profile-seattle-childrens-hospital/), and we will continue to profile successful sites and learn from their experiences.
The Childhood Arthritis and Rheumatology Research Alliance (CARRA), Inc. announced today that the first two patients had enrolled in the Start Time Optimization in Polyarticular Juvenile Idiopathic Arthritis (STOP-JIA) project. STOP-JIA aims to answer a critical question facing patients and doctors: “When is the best time to start biologic medications in polyarticular JIA?”
By Jay Mehta, MD
As the parent of a 4-year-old, and the resident of a major metropolitan area, the word “share” (and its various constructions) is a daily part of my lexicon. I’m constantly reminding my daughter the importance of “sharing” (which she thinks is giving her friends the toy that she doesn’t want to play with). The other day I took an Uber, and on my last vacation, I stayed in a house I found on AirBnB, both of which are parts of the “sharing economy.” And yesterday, I “shared” with my Twitter followers an interesting article on medical education.
CARRA is part of a new national research network called PARTNERS, which links researchers, patient communities, clinicians, and health care systems.
STOP–JIA is a prospective, observational study comparing the clinical effectiveness and impacts on patient-reported outcomes of three different treatment strategies (CTPs) in new onset pJIA patients to answer the question of when to start biologic medications.
View the STOP-JIA Prezi.